Kras activation (20-30%) and Trp53 loss of function (50-70%) are common mutational events in human non small cell lung cancer, and particularly in lung adenocarcinoma (LUAD), the most common type of lung cancer in patients 2,3. This evidence concerns the gene KRAS and lung carcinoma.